Article Text

Download PDFPDF
Unusual primary central nervous system T-cell/histiocyte-rich large B-cell lymphoma: a case report
  1. Jaime Toro1,2,
  2. Jorge Patiño1,
  3. Adriana Flórez1 and
  4. Juan Sebastian Rivera3
  1. 1Department Neurology, Hospital Universitario−Fundación Santa Fe de Bogotá, Bogotá, Colombia
  2. 2Universidad de Los Andes, Bogotá, Colombia
  3. 3Neurology, Fundacion Santa Fe de Bogota, Bogotá, Colombia
  1. Correspondence to Dr Jaime Toro; jtoro{at}


We report the case of a 54-year-old immunocompetent woman who presented with a primary T-cell/histiocyte-rich large B-cell lymphoma (TCHRLBCL) of the central nervous system without systemic involvement, diagnosed by means of a brain biopsy. She was treated with corticosteroids and we subsequently started chemotherapy with rituximab, methotrexate, ifosfamide and intrathecal cytarabine. The patient’s symptoms gradually improved over the first weeks and we followed-up with autologous haematopoietic cell transplantation. The patient has been in complete remission for a year. Primary TCHRLBCL of the central nervous system in an immunocompetent patient is an extremely rare condition that requires a multidisciplinary approach. This case highlights the importance of undergoing a sequential work-up and establishing a treatment despite the absence of evidence-based guidelines.

  • radiology (diagnostics)
  • malignant disease and immunosuppression
  • neurology (drugs and medicines)

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors JT, JSR, AF and JP contribute in drafting/revising the manuscript for content, including medical writing for content; study concept and design; obtaining funding and study supervision.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests JT is associate editor of NEJM Journal Watch Neurology and is an editorial board member for Multiple Sclerosis and Related Disorders. JP, JSR and AF have nothing to disclose.

  • Provenance and peer review Not commissioned; externally peer reviewed.